We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+10.12%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$369M
AUM Growth
–
Cap. Flow
+$418M
Cap. Flow %
113.21%
Top 10 Hldgs %
90.12%
Holding
16
New
16
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$140M
2
AXSM icon
Axsome Therapeutics
AXSM
+$66M
3
RLMD icon
Relmada Therapeutics
RLMD
+$34M
4
ETNB
89bio
ETNB
+$27.8M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$25.7M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 88.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNST
1
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$126M 34.2%
+4,016,873
New +$140M
AXSM icon
2
Axsome Therapeutics
AXSM
$11.2B
$47.7M 12.91%
+810,000
New +$66M
RLMD icon
3
Relmada Therapeutics
RLMD
$557M
$28.7M 7.79%
+842,814
New +$34M
TRIL
4
DELISTED
Trillium Therapeutics Inc.
TRIL
$27.4M 7.43%
+6,790,000
New +$25.7M
ETNB
5
DELISTED
89bio
ETNB
$24M 6.51%
+952,200
New +$27.8M
INO icon
6
Inovio Pharmaceuticals
INO
$55.7M
$21.6M 5.84%
+241,667
New +$14.9M
TXG icon
7
10x Genomics
TXG
$6B
$18.7M 5.06%
+300,000
New +$23.4M
MRSN
8
DELISTED
Mersana Therapeutics
MRSN
$15.3M 4.14%
+104,956
New +$18.3M
MRNS
9
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$13.2M 3.58%
+1,625,710
New +$14.1M
VSTM icon
10
Verastem
VSTM
$510M
$9.82M 2.66%
+310,078
New +$7.78M
ADVM
11
DELISTED
Adverum Biotechnologies
ADVM
$9.71M 2.63%
+99,438
New +$11.6M
ISEE
12
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.9M 2.41%
+2,586,537
New +$15.1M
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$8.4M 2.28%
+1,057,827
New +$8.13M
SRRA
14
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.82M 1.31%
+491,017
New +$6.43M
SPRO icon
15
Spero Therapeutics
SPRO
$67.7M
$3.83M 1.04%
+474,015
New +$4.18M
PTGX icon
16
Protagonist Therapeutics
PTGX
$8.79B
$799K 0.22%
+113,140
New +$848K

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q1 2020 Portfolio in Review

Q1 2020 is the first quarter with a 13F filing on record for VR Adviser, which disclosed 16 positions worth $369M. Its ten largest holdings account for 90% of the portfolio.

Its largest position is Constellation Pharmaceuticals, Inc.: 4,016,873 shares worth $126M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets.

  • VR Adviser's largest Q1 2020 buy was Constellation Pharmaceuticals, Inc.: 4,016,873 shares worth $126M.
  • VR Adviser's ten largest holdings make up 90% of its $369M portfolio in Q1 2020.
  • VR Adviser disclosed 16 positions in Q1 2020, its first 13F filing on record.

Based on VR Adviser's 13F filing for Q1 2020, filed 15 May 2020.